Sara Alkner

1.1k total citations
29 papers, 511 citations indexed

About

Sara Alkner is a scholar working on Cancer Research, Genetics and Oncology. According to data from OpenAlex, Sara Alkner has authored 29 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Cancer Research, 12 papers in Genetics and 11 papers in Oncology. Recurrent topics in Sara Alkner's work include Breast Cancer Treatment Studies (20 papers), Estrogen and related hormone effects (9 papers) and HER2/EGFR in Cancer Research (8 papers). Sara Alkner is often cited by papers focused on Breast Cancer Treatment Studies (20 papers), Estrogen and related hormone effects (9 papers) and HER2/EGFR in Cancer Research (8 papers). Sara Alkner collaborates with scholars based in Sweden, Denmark and Greece. Sara Alkner's co-authors include Lisa Rydén, Mårten Fernö, Pär‐Ola Bendahl, Anna Ehinger, M. Kügele, Sofie Ceberg, Anneli Edvardsson, Annika Jögi, Linda Hartman and Lars Olsson and has published in prestigious journals such as PLoS ONE, Cancer Research and The Lancet Oncology.

In The Last Decade

Sara Alkner

26 papers receiving 502 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sara Alkner Sweden	12	244	189	157	138	135	29	511
Trine Jakobi Nøttrup Denmark	8	248 1.0×	353 1.9×	236 1.5×	226 1.6×	188 1.4×	18	674
Andrea Marshall United Kingdom	9	241 1.0×	176 0.9×	163 1.0×	134 1.0×	113 0.8×	21	415
Itai Pashtan United States	11	121 0.5×	113 0.6×	153 1.0×	87 0.6×	164 1.2×	25	504
Gang Cai China	15	225 0.9×	97 0.5×	123 0.8×	91 0.7×	183 1.4×	47	524
Hekun Jin China	12	147 0.6×	174 0.9×	227 1.4×	235 1.7×	107 0.8×	26	580
Tse-Kuan Yu United States	9	208 0.9×	61 0.3×	96 0.6×	55 0.4×	229 1.7×	9	382
George Papadatos Australia	8	360 1.5×	75 0.4×	59 0.4×	103 0.7×	261 1.9×	15	505
Gabriela Gohla Canada	9	263 1.1×	60 0.3×	33 0.2×	78 0.6×	90 0.7×	15	363
Tanja Skyttä Finland	15	189 0.8×	244 1.3×	204 1.3×	327 2.4×	107 0.8×	46	649
T. Jansson Sweden	6	152 0.6×	49 0.3×	95 0.6×	192 1.4×	125 0.9×	6	380

Countries citing papers authored by Sara Alkner

Since Specialization

Citations

This map shows the geographic impact of Sara Alkner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Alkner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Alkner more than expected).

Fields of papers citing papers by Sara Alkner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Alkner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Alkner. The network helps show where Sara Alkner may publish in the future.

Co-authorship network of co-authors of Sara Alkner

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Alkner. A scholar is included among the top collaborators of Sara Alkner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Alkner. Sara Alkner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cronin‐Fenton, Deirdre, Signe Borgquist, Sara Alkner, et al.. (2025). Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study. British Journal of Cancer. 132(9). 828–836. 1 indexed citations

Alkner, Sara, et al.. (2025). Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study. BJS Open. 9(2).

Kjellén, Elisabeth, et al.. (2025). Internal mammary node irradiation in early breast cancer – target coverage and implications on dose to organs at risk. Acta Oncologica. 64. 989–996.

Boniface, Jana de, Tove Filtenborg Tvedskov, Jan Frisell, et al.. (2024). Abstract GS02-06: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial. Cancer Research. 84(9_Supplement). GS02–6.

Appelgren, Matilda, Robert Szulkin, Sara Alkner, et al.. (2024). Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. The Lancet Oncology. 25(9). 1222–1230. 9 indexed citations

Alkner, Sara, Dan Lundstedt, Martin Berg, et al.. (2024). Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. Radiotherapy and Oncology. 197. 110372–110372. 4 indexed citations

Alkner, Sara, Jana de Boniface, Dan Lundstedt, et al.. (2023). Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial. BMJ Open. 13(9). e075543–e075543. 7 indexed citations

Lempart, Michael, Martin Nilsson, Jonas Scherman, et al.. (2022). Pelvic U-Net: multi-label semantic segmentation of pelvic organs at risk for radiation therapy anal cancer patients using a deeply supervised shuffle attention convolutional neural network. Radiation Oncology. 17(1). 114–114. 8 indexed citations

Medin, Joakim, et al.. (2022). Prospective Clinical Feasibility Study for MRI-Only Brain Radiotherapy. Frontiers in Oncology. 11. 812643–812643. 16 indexed citations

10.

Medin, Joakim, et al.. (2021). Clinical validation of a commercially available deep learning software for synthetic CT generation for brain. Radiation Oncology. 16(1). 66–66. 37 indexed citations

11.

Sjöström, Martin, et al.. (2020). Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. PLoS ONE. 15(4). e0231786–e0231786. 17 indexed citations

12.

Lundstedt, Dan, Fredrika Killander, Erik Holmberg, et al.. (2019). Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. International Journal of Radiation Oncology*Biology*Physics. 105(2). 285–295. 11 indexed citations

13.

Jögi, Annika, Anna Ehinger, Linda Hartman, & Sara Alkner. (2019). Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer. PLoS ONE. 14(12). e0226150–e0226150. 60 indexed citations

14.

Alkner, Sara, Maj‐Britt Jensen, Birgitte Rasmussen, et al.. (2017). Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98. Breast Cancer Research and Treatment. 166(2). 481–490. 7 indexed citations

15.

Alkner, Sara, Man‐Hung Eric Tang, Christian Brueffer, et al.. (2015). Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. Breast Cancer Research. 17(1). 102–102. 29 indexed citations

16.

Sandberg, Maria, Sara Alkner, Mikael Hartman, et al.. (2012). Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast cancer. International Journal of Cancer. 132(10). 2388–2394. 1 indexed citations

17.

Alkner, Sara, et al.. (2012). The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor. Annals of Oncology. 24(5). 1244–1252. 10 indexed citations

18.

Alkner, Sara, Pär‐Ola Bendahl, Mårten Fernö, Jonas Manjer, & Lisa Rydén. (2011). Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer. 11(1). 114–114. 32 indexed citations

19.

Alkner, Sara, Pär‐Ola Bendahl, Mårten Fernö, Bo Nordenskjöld, & Lisa Rydén. (2009). Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. European Journal of Cancer. 45(14). 2496–2502. 31 indexed citations

20.

Alkner, Sara, Pär‐Ola Bendahl, Dorthe Grabau, et al.. (2009). AIB1 is a predictive factor for tamoxifen response in premenopausal women. Annals of Oncology. 21(2). 238–244. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact